Kilitch Drugs (India) Ltd Q4 FY23 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 2
Margin
Category 2
Fundraise
Yes
Order
N/A
Capex
Yes
2 of 4 growth signals are positive.
Full analysisRevenue guidance
Category 2- Company expects robust growth in Ethiopia business in FY 2023-24 as government has agreed in principle to provide foreign exchange to support imports, enabling full utilization of Cephalosporin plant capacity.
- Overall sales growth of 30% to 35% year-on-year was reported, with export commissions rising in line with sales.
- Indian pharmaceutical market projected to see double-digit growth, driven by potential increases in government healthcare spending.
- Injectable business expected to grow with plans for increased capacity at Khopoli plant; running multiple shifts planned to meet growing demand.
- Exports from the Ethiopian plant to other African countries (Sudan, Uganda, Kenya, Tanzania, Nigeria) anticipated within 1-2 years after product registration and approvals.
- Capacity expansions and government contracts are expected to drive increased production volumes and revenues.
- Continued focus on contract manufacturing and exploring opportunities to monetize non-core land assets for capital deployment.
See what Kilitch Drugs (India) Ltd management said on margin guidance — free account, 30 seconds.
Fundraise plans
Yes- The company plans to fund the Khopoli plant expansion primarily through external loans, with bank sanctions already obtained for the funding.
- There is no mention of any planned equity fundraising related to this expansion or otherwise.
- For non-core assets like land in Bhiwandi, monetization might be considered at the right time, but the current focus remains on pharma operations and the capex projects.
- The company aims to sustain growth through internal accruals and bank funding rather than new equity issuance.
See what Kilitch Drugs (India) Ltd management said on order book — free account, 30 seconds.
Capex plans
Yes- Khopoli Plant Expansion:
- - Estimated capital expenditure: More than INR 100 crores.
- - Funding: Mostly through external bank loans; sanctions have been received.
- - Timeline: Plant construction to take about two years; production expected to start from March 2025 onwards.
- - Capacity details to be consolidated and shared later.
- Ethiopia Plant:
- - Current operations ramping up after initial struggles.
- - Plans to increase supply and possibly export within African countries.
- - Government support with tax benefits: Four years of income tax exemption starting July 2021 till July 2025.
- Non-core assets:
- - Land in Bhiwandi may be monetized at the right opportunity but focus remains on pharma-related capex.
- Overall, strategic investments focus on expanding manufacturing capacity to meet growing demand in both domestic and export markets.
Track Kilitch Drugs (India) Ltd — get its next earnings analysis in your feed
Margin guidance
Category 2- Kilitch Drugs India Limited expects continued robust growth in earnings and profits driven by multiple factors.
- Domestic pharma market anticipated to grow at double-digit rates, supported by increased government healthcare spend.
- Ethiopian manufacturing unit poised for a robust ramp-up, with government backing and forex allocation improving operational capacity.
- EBITDA margins have shown improvement (from 14.8% to 18.8%) and management aims for further margin enhancements in coming quarters.
- New Khopoli plant expansion (> INR 100 crores capex) will augment capacity, supporting growth, especially in contract manufacturing.
- EPS grew significantly to INR 10.09 in FY23 from INR 6.76, with management optimistic on sustaining this growth trajectory.
- Overall, growth will be fueled by expansion in both domestic and export markets, capacity ramp-ups, and operational efficiencies.
Order book
- No specific numeric details on the current or expected order book were mentioned in the transcript.
- The management expressed confidence in demand growth, citing an 8% to 12% year-on-year growth trend in the pharma market.
- The additional capacity at the Khopoli plant was conceptualized anticipating increased demand and possible capacity shortfalls.
- While no formal offtake agreements for the new capacity were signed, the company expects existing customers to create demand based on market trends.
- In Ethiopia, government tenders have been delayed due to forex issues but are expected to be addressed soon, potentially boosting orders.
- The private market currently accounts for Ethiopian sales, with supply to government expected to start after forex support.
- Overall, management is optimistic about a robust sales ramp-up with capacity expansions supporting growth.
How does Kilitch Drugs (India) Ltd rank vs peers in Pharmaceuticals & Biotechnology?
Pro featureHow does Kilitch Drugs (India) Ltd rank in Pharmaceuticals & Biotechnology?
Compare Kilitch Drugs (India) Ltd against every Pharmaceuticals & Biotechnology company (Q4 FY23) on revenue, margins and earnings-call signals.
Continue your research
What Kilitch Drugs (India) Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- IOL Chemicals (Q1 FY27)
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
- Innova Captab Ltd (Q1 FY27)
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
- Glenmark Pharma. (Q1 FY27)
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…
- Strides Pharma Science Ltd (Q1 FY27)
markets continue to be broad-based growth drivers, with 17% YoY growth and expansion in B2B and B2C markets including Europe, UK, Nordics, Africa, LATAM, MENA…